Triclosan exposure and in vitro fertilization treatment outcomes in women undergoing in vitro fertilization

Paweł Radwan1,2 · Bartosz Wielgomas3 · Michał Radwan4,5 · Rafał Krasiński6 · Anna Klimowska3 · Radosław Zajdel6 · Dorota Kaleta7 · Joanna Jurewicz7

Received: 2 July 2020 / Accepted: 15 October 2020 / Published online: 23 October 2020
© The Author(s) 2020

Abstract
Triclosan (TCS) is a widespread environmental endocrine-disrupting chemical. Animal and in vitro studies suggested that triclosan may affect homeostasis of sex and thyroid hormones and impact on reproduction. Due to limited data derived from human epidemiological studies, this study was performed to examine the association between urinary concentration of triclosan and in vitro reproductive outcomes (methaphase II (MII) oocyte yield, top quality embryo, fertilization rate, implantation rate, and clinical pregnancy) among women from infertility clinic. The study participants were enrolled in an Infertility Center in Poland. A total of 450 women aged 25–45 (n = 674 IVF cycles) provided urine samples. The urinary concentrations of triclosan were evaluated using validated gas chromatography ion-tap mass spectrometry method. Clinical outcomes of IVF treatment were abstracted from patients electronic chart records. Triclosan was detected in urine of 82% of women with geometric mean 2.56 ± 6.13 ng/mL. Urinary concentrations of triclosan were associated with decrease implantation rate (p = 0.03). There were no association between other examined IVF outcomes: MII oocytes, embryo quality, fertilization rate, and exposure to triclosan. As this is one of the first study on this topic, studies among larger and more diverse population are needed to confirm the results.

Keywords Early IVF outcomes · Urinary triclosan concentrations · Environmental exposure · Implantation rate · Clinical pregnancy · Top quality embryo

Introduction
Man-made, widespread, environmental chemicals which have been used widely for decades have the ability to disrupt hormonal homeostasis and affect human fertility. One of this chemicals is triclosan (TCS) used in personal care products such as soaps and toothpaste, household products, and pharmaceuticals as broad-spectrum antibacterial additives (Yuan et al. 2015). Because of widespread usage of triclosan, there is the potential for the general population to be exposed to triclosan.

Environmental exposure to triclosan may occur via consumer products that contain TCS, but also through water and/or food products contaminated with TCS (Weatherly and Gosse 2017). Detectable levels of TCS were found in milk and blood of nursing mothers (0.25–2.1 µg/L) (Allmyr et al. 2006) and human urine (2.4–3.7 µg/L) (Calafat et al. 2008). After oral exposure, urinary excretion increases in humans within 24 h. During the first 4 days after exposure, between 24 and 83% of the consumed TCS is excreted, and after 8 days, excretion approaches baseline levels (Sandborgh-Englund et al. 2006).
Triclosan has been reported to act as endocrine disrupting chemical in many in vitro, animal, and also human studies (Axelstad et al. 2013; Louis et al. 2017). Recent animal studies correlated TCS exposure with adverse reproductive effects. Exposure to TCS on certain gestational days decreased implantation rates in mice (Crawford and Decatanzaro 2012). In the study performed by Hwang et al. (2014), embryos are treated with higher than 1.0 μM levels of TCS displayed arrested development. Human studies on potential effect on reproduction and fertility, especially early IVF outcomes are limited and inconclusive. Lange et al. (2015) found that TCS concentrations in urine decrease oocyte yield. Other examined clinical IVF outcomes (implantation rate, pregnancy rate, or live birth rate) were not related to such exposure (Lange et al. 2015). Recently, published study by Hua et al. (2017) found the negative effect of TCS exposure on top quality embryo and implantation rate (Hua et al. 2017).

The aim of the study was to investigate the effect of environmental exposure to triclosan and early reproductive outcomes (MII oocyte count, top quality embryo, fertilization rate, implantation rate, and clinical pregnancy). According to our best knowledge, the current study is the largest human epidemiological study addressing the topic of triclosan exposure and early adverse reproductive outcomes.

Materials and methods

Study participants and data collection

A total of 450 women between 25 and 45 years of age seeking infertility treatment at Gameta Hospital reproductive centre certified by the European Society for Human Reproduction and Embryology (ESHRE ART Center Certification for good clinical practice, 2019, C-0001) and that underwent at least one fresh in vitro fertilization cycle (> 1.5 ng/ml) on day of final follicle maturation, underwent IVF-ICSI treatments and recruited. The couples’ exclusion criteria were as follows: fertilization failure during the previous IVF-ICSI attempt, sperm concentration < 1 million per mL, azoospermia, ovarian hyperstimulation syndrome, abnormal pelvic ultrason sound examination (abnormal uterine cavity, hydrosalpinx, ovarian cysts), endocrinologic disorders (POCS (polycystic ovary syndrome)), menstrual disorders, chlamydia infection, thyroid disfunction (TSH > 2.5 μU/mL, BMI > 40 kg/m²). The Bioethical Committee in Lodz, Poland, approved the study (resolution no 23/2014). At the time of recruitment, study subjects received written informed consents before their participation and completed a questionnaire about socio-demographic characteristics, medical, especially gynecological history, chronic diseases, lifestyle factors, and occupational factors. The participant’s date of birth was collected at entry, and weight and height were measured by trained study staff. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared.

Clinical data assessment

Participants’ clinical data were received from the medical electronic charts record. Concentration of hormones: follicle-stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH), and progesterone, were assessed in serum using chemiluminescence immunoassay between second and third day of menstrual cycle. Serum was analyzed for antimüllerian hormone (AMH) with an enzyme-linked immunoabsorbent method utilizing commercially available Gen-II ELISA kits according to manufacturer instruction (Beckman Coulter, Inc., USA). The highest level of oestradiol prior to oocyte retrieval was treated as the peak oestradiol level.

Ovarian stimulation and ovum pick up

The long agonist or short antagonist protocol was used to stimulate ovulation. The administrated drugs were recombinant FSH (rFSH) or human menopausal gonadotropin (hMG) at a daily dose of 150–300 IU. In long protocol, patients daily received GnRH agonist (0.1 mg Gonapeptyl, Ferring Pharmaceuticals) and transvaginal ultrasound examination and measuring the serum level of estradiol (E2) were used to monitor the growth of follicles. In short antagonist protocol, the ovarian stimulation was started on the second day of the cycle. The patients were administered 0.25 mg of Ganirelux (Orgalutran, Organon) when mean diameter one of the follicles was bigger than 14 mm or when the estradiol level was above 400 pg/mL. After the diameter of the follicles was above 17 mm and the estradiol level was above 200 pg/mL per one follicle, the patient was administered subcutaneously 250 μg rhCG (Ovitrelle, Merck-Serono) or 0.2 mg triptorelin (0.1 Gonapeptyl Daily, Ferring). Ovarian pick up (OPU) was preformed general intravenous anesthesia 36 h following the injection of rCG/GnRH analogue. In order to supplement the luteal phase, the patients were intravaginally administered 2 × 200 mg micronized progesterone (Luteina, Adamed, Poland) and 3 × 10 mg oral dydrogesterone (Duphaston, Mylan Healthcare, Poland). In case of an increased risk of ovarian hyperstimulation syndrome (OHSS, defined as at least, 14 follicles of ≥ 11 mm) or an elevated progesterone concentration (> 1.5 ng/ml) on day of final follicle maturation, a “freeze all” strategy was employed.

Oocyte preparation

Retrieved follicular fluid was examined under a microscope to identify and isolate cumulus-oocyte complexes (COC). Once retrieved, COC were placed in G-IVF PLUS (Vitrolife,
Sweden) and preincubated for 2 h at 37 °C, 6% CO₂, 5% O₂ before denudation. Granulosa cells from COC were removed in two-step procedure: initial enzymatic digestion in a solution of 80 IU/mL hyaluronidase (Vitrolife, Sweden) followed by mechanical removal in G-MOPS PLUS (Vitrolife, Sweden). Quality and maturity of each oocyte were assessed under an inverted microscope. Oocytes were classified as follows: germinal vesicle (GV), metaphase I (MI), metaphase II (MII), or degenerated. The oocytes which achieved the metaphase of the second meiotic division (MII) were incubated in G-1 PLUS (Vitrolife, Sweden) for 1–2 h before fertilization.

**Sperm preparation**

Sperm preparation was proceeded by centrifugation in QUINN’s Sperm Washing Medium (SAGE, USA) at 250 g for 10 min. Before the ICSI procedure, the spermatozoa were immobilized in the drop of 7% PVP (Polyvinylpyrrolidone, SAGE, USA). Intracytoplasmic sperm injection was performed for all patients with a standard micromanipulators (Narishige, Japan) and inverted microscope (Nikon, Japan/Leica, Germany). Spermatozoa was microinjected with a × 200 magnitude in a drop of G-MOPS PLUS (Vitrolife, Sweden). After ICSI, oocytes were allocated into 500 µL of G-1 PLUS culture medium (Vitrolife, Sweden) in four-well dishes (Nunc, USA) and cultured at 37 °C, 6% CO₂, 5% O₂. In day 3, G-1 PLUS culture medium was replaced with G-2 PLUS (Vitrolife, Sweden).

**Oocyte fertilization**

An intracytoplasmic sperm injection was performed for all patients with a standard micromanipulators (Narishige, Japan) and inverted microscope (Narishige, Nikon, Japan). Spermatozoa was microinjected with a × 200 magnitude in a drop of G-MOPS PLUS (Vitrolife, Sweden). Fertilized oocytes were placed in four-well dishes (Nunc, USA) in 500 µL G-1 PLUS (group Vitrolife). Zygotes and embryos were cultured in sequential medium (G-1 PLUS/G-2 PLUS, Vitrolife, Sweden). The culture was conducted in standard conditions (6% CO₂ and 5% O₂, 37 °C) using HeraCell 150 incubators (Thermoscientific, Germany).

**Embryo assessment**

Zygotes were assessed on the basis of two pronuclei and two polar bodies in the perivitelline space 16–18 h following the application of the IVF-ICSI procedure. In days 2 and 3 (respectively, 43–45 and 67–69 h following the microinjection), the embryos were evaluated in terms of the number, size, symmetry of blastomers, multinucleation, and degree of fragmentation (grade A, B, C, D). Top quality embryos were defined as grade A and B in day 3. Blastocysts in day 5 and day 6 (114–118 and 138–142 h following the IVF-ICSI procedure) were assessed on the base of the classification of the blastocoels and the degree of embryonic expansion. The embryoblast and trophoblast were scored in expanded blastocyst according to modified Gardner scoring system (Gardner et al. 2000).

The percentage of embryos with successful implantation compared to the number of embryos transferred was treated as the implantation rate. Clinical pregnancy was recognized when ß-hCG level increased and the confirmation of an intrauterine pregnancy on an ultrasound at 6 weeks.

**Assessment of urinary triclosan concentrations**

Urine samples were collected in a polypropylene cup. During each IVF-ICSI cycle, at least one urine sample was provided just before egg-retrieved procedure. A handheld refractometer was used to assessed specific gravity (SG). The concentration of triclosan was measured using gas chromatography (Varian GC-450) coupled with tandem mass spectrometry (Varian 220-MS, ion-trap mass spectrometer as previously described (Jurewicz et al. 2019)). External quality control was carried out by participation in the German External Quality Control Scheme (G-EQUAS), organized, and managed by the Institute and the Outpatient Clinic for Occupational, Social, and Environmental Medicine of the University of Erlangen-Nuremberg (Erlangen, Germany). Scheme, evaluation, and certification are based on the German Federal Medical Council (http://www.g-equas.de/). Analytical laboratory of the Department of Toxicology, Medical University of Gdańsk, successfully participated in this external quality check for triclosan.

**Statistical analysis**

Demographic, baseline, and clinical characteristics of the study participants are presented using mean ± standard deviations (SD) or percentages. Urinary triclosan concentrations were categorized into quartiles. The lowest quartile (< LOD to 25th) was considered as the reference group. Other categories of exposure were as follows: > 25th to 50th, > 50th to 75th, > 75th. Additionally, triclosan exposure was presented as continuous variable.

The levels of triclosan < LOD were assigned as half of LOD (Hornung and Reed 1990) and adjusted for urine dilution by specific gravity (SG) using the following formula: 

\[P_c = P \left( \frac{1.016^\text{SG}}{\text{SG}} - 1 \right)\]

where \(P\) is the measured triclosan concentration (μg/L), \(P_c\) is the SG-corrected triclosan concentration (μg/L), \(P\) is the measured triclosan concentration, and 1.016 is treated as the median SG level among study participants (Hornung and Reed 1990). The triclosan concentrations were natural-log transformed (\(x + 1\)) to normalize distributions.
To explore the effect of triclosan exposure on early reproductive outcomes, multivariable generalized linear mixed analyses with random intercepts were performed. The variables such as age, BMI, smoking status, and infertility diagnosis were treated as the confounding factors. The level of statistical significance was set at 0.05. All statistical analysis were performed using R statistical software (ver.3) (R Core Team 2016).

**Results**

Table 1 presents the demographic and medical characteristics of the study population. The mean age and BMI of participants were 31 years and 23.19 kg/m², respectively. A total of 65.11% and 32.00% of women had higher or secondary education, respectively. Ninety-two percent of study participants declared not smoking cigarettes. A total of 54.44% of women drank none or less than 1 drink per week. In case of the infertility diagnosis, it was male factor in 38%, idiopathic infertility in 30.89%, and female factor in 28.67% (Table 1).

The antral follicle count was 12.54 ± 7.21 in both ovaries. The mean level of FSH, E2, LH, and progesterone was 6.21 ± 1.13 IU/L, 92.78 ± 15.78 pg/mL, 5.34 ± 3.24 IU/L, and 0.99 ± 1.58 ng/mL, respectively (Table 1). The peak estradiol level was 2608.74 ± 1614.63 ng/mL (Table 1).

The characteristic of early IVF outcomes is included in Table 1. The mean ± SD number of oocytes retrieved, MII oocytes, embryos available, top quality embryos, and embryo transferred was 9.98 ± 7.22, 13.21 ± 7.44, 6.28 ± 1.54, 2.01 ± 2.48, and 1.95 ± 0.16, respectively. The fertilization rate and implantation rate was 80 ± 21% and 38.16 ± 2.79%, respectively. The rate of clinical pregnancy was 43.12 ± 7.89 (Table 1).

As shown in Table 2, triclosan was detected in 81.22%. The geometric mean of TCS and TCS SG-adjusted of the 562 samples provided by 450 women was 2.56 ng/mL and 2.87 ng/mL, respectively.

The associations between exposure to triclosan and early reproductive outcomes are presented in Table 3. In the first regression model adjusted for BMI, age, smoking, and infertility diagnosis, the significant association was observed between triclosan concentration (continuous variable) and implantation rate ($p = 0.047$). In the fourth quartile of TCS, exposure decrease in implantation rate was also observed ($p = 0.03$). No significant associations were observed between exposure to triclosan and MII oocyte count, embryo quality, fertilization rate, and clinical pregnancy (Table 3). When the model was additionally adjusted for AFC and protocol type, the results were similar. Triclosan negatively affects the implantation rate in the fourth quartile of exposure ($p = 0.04$) and as continuous variable ($p = 0.04$) (Table 3).

| Variables                 | n (%) | Mean ± SD |
|--------------------------|-------|-----------|
| Education                |       |           |
| Vocational               | 13 (2.89) |     |
| Secondary                | 144 (32.00) |   |
| Higher                   | 293 (65.11) |   |
| Age (years)              |       |           |
| 24–30                    | 81 (18.00) |     |
| 31–39                    | 342 (76.00) |   |
| 40–44                    | 27 (6.00) |     |
| BMI (kg/m²)              |       |           |
| <18.5                    | 26 (5.78) |     |
| 18.5–24.9                | 261 (58.00) |   |
| 25–29.9                  | 135 (30.00) |   |
| 30–40                    | 28 (6.22) |     |
| Current smoking          |       |           |
| No                       | 414 (92.00) |   |
| Yes                      | 36 (8.00) |     |
| Alcohol use              |       |           |
| None or < 1 drink/week   | 245 (54.44) |   |
| 1–3 drinks/week          | 198 (44.0) |     |
| Everyday                 | 7 (1.56) |     |
| Initial infertility diagnosis |       | |
| Male factor              | 171 (38.0) |   |
| Idiopathic               | 139 (30.89) |   |
| Endometriosis            | 62 (13.78) |   |
| Ovarian factor           | 21 (4.67) |     |
| Tubal factor             | 46 (10.22) |   |
| Missing data             | 11 (2.44) |     |
| Duration of couple’s infertility (years) |       | |
| 1–2                      | 34 (7.56) |     |
| 2–3                      | 121 (26.89) |   |
| 3–5                      | 131 (29.11) |   |
| >5                       | 164 (36.44) |   |
| Stimulation protocol     |       |           |
| Long GnRH agonist protocol | 198 (44) |   |
| GnRH-antagonist protocol | 252 (56) |     |
| AFC (n)                  | 12.54 ± 7.21 | |
| FSH (IU/L) (mean ± SD)   | 6.21 ± 1.13 |   |
| E2 peak (ng/mL)          | 2608.74 ± 1614.63 | |
| E2 (pg/mL)               | 92.78 ± 15.78 |   |
| Progesterone (ng/mL)     | 0.99 ± 1.58 |   |
| LH (IU/L)                | 5.34 ± 3.24 |   |
| AMH (ng/mL)              | 1.19 ± 1.22 |   |
| Number of oocytes retrieved (COC) | 13.21 ± 7.44 |   |
| Number of MII oocytes    | 9.98 ± 7.22 |   |
| Fertilization rate (%)   | 80 ± 21 |   |
| No. of cleavage embryos available | 6.28 ± 1.54 |   |
| No. of top quality embryos | 2.01 ± 2.48 |   |
| No. of embryos transferred | 1.95 ± 0.16 |   |
| Clinical pregnancy rate (%) per cycle | 43.12 ± 7.89 |   |
| Implantation rate (%) per embryo | 38.16 ± 2.79 |   |

SD, standard deviation; AMH, anti-Müllerian hormone; AFC, antral follicle count; FSH, follicle-stimulating hormone; E2, estradiol; LH, luteinizing hormone
Table 3  The association between triclosan level in urine and IVF outcomes

|          | MII oocyte count | Top quality embryo | Fertilization rate | Implantation | Clinical pregnancy |
|----------|------------------|---------------------|-------------------|--------------|-------------------|
|          | Coef 95% CI p    | Coef 95% CI p       | Coef 95% CI p     | Coef 95% CI p | Coef 95% CI p     |
| TCS      |                  |                     |                   |              |                   |
| Conta    | 0.04  -0.06; 0.27| 0.75                | -0.06 - 0.09; 0.13| 0.41         | -0.19 -0.40; -0.01| 0.047 |
| Contb    | 0.03  -0.05; 0.30| 0.77                | -0.04 - 0.06; 0.23| 0.57         | -0.17 -0.38; -0.02| 0.04 |
| Q2a      | 0.03  -0.06; 0.27| 0.82                | -0.19 - 0.43; 0.06| 0.13         | -0.02 -0.06; 0.09| 0.28 |
| Q2b      | 0.03  -0.04; 0.32| 0.81                | -0.12 - 0.22; 0.04| 0.09         | -0.02 -0.04; 0.12| 0.56 |
| Q3a      | 0.05  -0.06; 0.32| 0.72                | -0.03 - 0.06; 0.18| 0.77         | -0.04 -0.06; 0.17| 0.68 |
| Q3b      | 0.04  -0.04; 0.28| 0.73                | -0.04 - 0.05; 0.22| 0.82         | -0.04 -0.05; 0.36| 0.78 |
| Q4a      | 0.10  -0.06; 0.33| 0.38                | -0.08 - 0.09; 0.16| 0.50         | -0.05 -0.06; 0.28| 0.65 |
| Q4b      | 0.11  -0.04; 0.30| 0.40                | -0.06 - 0.07; 0.19| 0.56         | -0.04 -0.05; 0.32| 0.67 |

TCS, triclosan; Q2, (25–50) percentile (n = 95); Q3, (50–75) percentile (n = 62); Q4, > 75 percentile (n = 96); reference category to Q2, Q3, and Q4 is Q1 Q1 25 percentile (≤ n = 112); models adjusted for (a) BMI, age, smoking, and infertility diagnosis, (b) BMI, age, smoking, infertility diagnosis, protocol type, and AFC.

Discussion

In the current study, we assessed the exposure to triclosan and its association with early IVF outcomes: MII oocyte count, top quality embryos, fertilization rate, and implantation rate. The findings suggest that triclosan may have a negative impact on fertility, particularly on the implantation rate. The results are in line with previous studies that have demonstrated the effects of triclosan on reproduction, although the exact mechanism remains unclear.

References

Other studies performed on TCS exposure have assessed the effect of exposure to TCS on fertility, whereas the TCS exposure on human reproduction is mainly under researched and limited. Previous published studies suggest that triclosan may impact estrogen concentrations in estrogen levels which can lead to implantation failure in humans and animals (Ma et al., 2004; Gidley-Baird et al., 1996). The study performed among Canadian women (Smarr et al., 2017) found decrease in implantation rates and increase in gestational length in mice after exposure to triclosan. Other studies on exposure to triclosan and fertility, especially early IVF outcomes, remain unclear and limited. Previously published studies suggested a negative association between TCS exposure in second, third, and fourth quartile and fertility, which is in line with current study. On the other hand, Lang et al. (2017) found a negative association between TCS exposure and IVF outcomes. The differences in results may arise from the fact that the study was based on smaller sample size (n = 131) compared to our study (n = 459, 674 cycles) and the differences in the same may differ. Additionally, the sensitivity of female reproductive track to TCS exposure may vary depending on the body weight and number of other examined parameters of early IVF outcomes. Hua et al. (2017) observed that urinary TCS concentrations were negatively associated with the number of top quality embryos, and implantation rate among women undergoing in vitro fertilization, which is in line with the current study.
receptivity, embryo transport, and development. Berger et al. (2007) and Takai et al. (2000) also reported reduce implantation sites in animal.

Urinary levels of triclosan in our study were lower than those reported in for female US population in similar age in 2014 (CDC 2017). The median, 75 percentile, and geometric mean were 1.37 ng/mL, 2.55 ng/mL, and 2.56 ng/mL, respectively, in our study and among US females (6.20 ng/mL, 31.7 ng/mL, 9.63 ng/mL, respectively). On the other hand, the TCS concentrations were higher than that presented by Hua et al. (2017) among infertile patients undergoing their first IVF/ICSI in China (0.058 ng/mL, 0.064 ng/mL, 0.645 ng/mL).

To the best of our knowledge, the current study is the largest human study (n = 450 women) that explore the effect of triclosan exposure and early reproductive outcomes.

Strengths of our study include performing study in the same center, using the same standardized protocol. Detailed questionnaire data on demographics, medical, and lifestyle risk factors allowed for control of confounding in the statistical analysis. Also, all study participants provided at least 1 urine sample per cycle which in case of nonpersistent chemical with short half-lives is very important to confirm the exposure. Our study has also several limitations. It may be difficult to generalize the results to the general population as the study was conducted among women seeking infertility treatment. Additionally, the study is not able to show the mechanism of the observed associations, but the epidemiological study in their nature is not designed to study the mechanisms.

In conclusion, we found that urinary triclosan concentrations may affect early IVF outcome: implantation rate. As this is one of the first study, the confirmation of findings in larger studies is needed.

Authors’ contributions Pawel Radwan and Joanna Jurewicz were involved in study concept, design, and data interpretation. Michal Radwan was involved in data interpretation. Data analysis was performed by Radoslaw Zajdel. Pawel Radwan drafted the manuscript. Rafal Krasinski was responsible for embryological data assessment. Bartosz Wielgomas and Anna Klimowska were responsible for analysis of urinary level of triclosan. All authors provided substantial intellectual contributions and approved the final version of manuscript.

Funding RPMA.01.02.00-14-7576/17 Mazovia Regional Development Fund 2014-2020.

Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Compliance with ethical standards

Competing interests The authors declare that they have no conflict of interest.

Ethics approval and consent to participate The Bioethical Committee in Lodz, Poland, approved the study (resolution no 23/2014). All participants obtained and signed written informed consents prior to enrollment.

Consent to publish Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Allmyr M, Adolfsson-Erici M, McLachlan MS, Sandborgh-Englund G (2006) Triclosan in plasma and milk from Swedish nursing mothers and their exposure via personal care products. Sci Total Environ 372:87–93
Axelstad M, Boberg J, Vinggaard AM, Christiansen S, Hass U (2013) Triclosan exposure reduces thyroxine levels in pregnant and lactating rat dams and in directly exposed offspring. Food Chem Toxicol 59:534–540
Berger RG, Hancock T, deCatanzaro D (2007) Influence of oral and subcutaneous bisphenol-A on intrauterine implantation of fertilized ova in inseminated female mice. Reprod Toxicol 23(2):138–144
Calafat AM, Ye X, Wong LY, Reddy JA, Needham LL (2008) Urinary concentrations of triclosan in the U.S. population: 2003–2004. Environ Health Perspect 116:303–307
CDC (Centers for Disease Control and Prevention). Fourth national report on human exposure to environmental chemicals (NHANES). Updated Tables, January, 2017. United States Department of Health and Human Services. Centers for Disease Control and Prevention. 2017.
Crawford BR, Decatanzaro D (2012) Disruption of blastocyst implantation by triclosan in mice: impacts of repeated and acute doses and
combination with bisphenol-A. Reprod Toxicol 34:607–613. https://doi.org/10.1016/j.reprotox.2012.09.008

Gardner DK, Lane M, Schoolcraft WB (2000) Culture and transfer of viable blastocytes: a feasible proposition for human IVF. Hum Reprod 15(Suppl 6):9–23

Gidley-Baird AA, O’Neill C, Sinosich MJ, Porter RN, Pike IL, Saunders DM (1986) Failure of implantation in human in vitro fertilization and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice. Fertil Steril 45(1):69–74

Hornung RW, Reed LD (1990) Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 5(1):46–51

Hua R, Zhou Y, Wu B, Huang Z, Zhu Y, Song Y, Yu Y, Li H, Quan S (2017) Urinary triclosan concentrations and early outcomes of in vitro fertilization-embryo transfer. Reproduction 153(3):319–325

Ishibashi H, Matsumura N, Hirano M, Matsuoka M, Shiratsuchi H, Ishibashi Y, Takao Y, Arizono K (2004) Effects of triclosan on the early life stages and reproduction of medaka Oryzias latipes and induction of hepatic vitellogenin. Aquat Toxicol 67(2):167–179

Jurewicz J, Wielgomas B, Radwan M, Karwacka A, Klimekowska A, Dziewirska E, Korczak K, Zajdel R, Radwan P, Hanke W (2019) Triclosan exposure and ovarian reserve. Reprod Toxicol 89:168–172

Koury T, Vélez MP, Arbuckle TE, Fraser WD (2015) Female exposure to phenols and phthalates and time to pregnancy: the Maternal-Infant Research on Environmental Chemicals (MIREC) Study. Fertil Steril 103(4):1011–1020

Weatherly LM, Gosse JA (2017) Triclosan exposure, transformation, and human health effects. J Toxicol Environ Health B Crit Rev 20(8):447–469

Wolstenholme JT, Rissman EF, Connelly JI (2011) The role of Bisphenol A in shaping the brain, epigenome and behavior. Horm Behav 59(3):296–305

Xiao S, Diao H, Smith MA, Song X, Ye X (2011) Preimplantation exposure to bisphenol A (BPA) affects embryo transport, preimplantation embryo development, and uterine receptivity in mice. Reprod Toxicol 32(4):434–441

Yuan M, Bai M-Z, Huang X-F, Zhang Y, Liu J, Hu M-H, Zheng W-Q, Jin F (2015) Preimplantation exposure to bisphenol A and triclosan may lead to implantation failure in humans. Biomed Res Int 2015:184845

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.